INmune Bio, Inc. (NASDAQ:INMB) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants David Moss – Co-Founder and Chief Financial Officer RJ Tesi – Co-Founder and Chief Executive Officer Mark Lowdell – Co-Founder and Chief Scientific Officer Conference Call Participants Tom Shrader – BTIG William Wood – B. Riley Daniel Carlson – TW Research Group Operator Greetings, and welcome to the INmune Bio Second Quarter 2022 Earnings Call. At this time, all participants are in a listen-only m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Nevada 47-5205835 Identification No.) David Moss 225 NE Mizner Blvd., Suite 6 ...

INmune Bio, Inc. (NASDAQ:INMB) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants David Moss – Co-Founder and Chief Financial Officer RJ Tesi – Chairman and Chief Executive Officer CJ Barnum – Head of Neuroscience Conference Call Participants William Wood – B. Riley Securities Matthew Cross – Alliance Global Partners Sung Hong – BTIG Daniel Carlson – TW Research Group Operator Greetings, and welcome to the INmune Bio First Quarter 2022 Earnings Call. At this time, all participants ...

FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (State of incorporation) (I.R.S. Employer Identification No.) David Moss 225 NE Mizner Blvd., Suite 640 Boca Raton, FL ...

INmune Bio, Inc. (NASDAQ:INMB) Q4 2021 Earnings Conference Call March 3, 2022 4:30 PM ET Company Participants David Moss - Co-Founder and Chief Financial Officer Raymond J. Tesi - Chief Executive Officer and Co-Founder Conference Call Participants Tom Shrader - BTIG Mayank Mamtani - B. Riley Securities Matthew Cross - Alliance Global Partners Operator Greetings and welcome to the INmune Bio Fourth Quarter and Full Year 2021 Earnings Call. At this time, all participants are in a listen-only mode. A question- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-38793 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 (State or other jurisdiction of inco ...

INmune Bio, Inc. (NASDAQ:INMB) Q3 2021 Earnings Conference Call November 3, 2021 4:30 PM ET Company Participants David Moss - Co-Founder and Chief Financial Officer R. J. Tesi - Chief Executive Officer and Co-Founder Mark Lowdell - Chief Scientific Officer and Co-Founder C. J. Barnum - Head, Neuroscience Conference Call Participants Tom Shrader - BTIG Operator Greetings and welcome to the INmune Bio Third Quarter 2021 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 (State of incorporation) (I.R.S. Employer Identification No.) David Moss 225 NE Mizner Blvd., Su ...

INmune Bio, Inc. (NASDAQ:INMB) Q2 2021 Results Conference Call August 4, 2021 4:30 PM ET Company Participants David Moss - Co-Founder and CFO Dr. RJ Tesi - CEO and Co-Founder Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Mikhail Keyserman - BTIG Mayank Mamtani - B. Riley Securities Mark Lowdell - Chief Scientific Officer and Chief Manufacturing Officer Daniel Carlson - TW Research Operator Greetings, and welcome to the INmune Bio Second Quarter 2021 Earnings Call. [Operator Instructi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 INMUNE BIO INC. (Exact name of registrant as specified in its charter) Nevada 47-5205835 Boca Raton, FL 33432 (Address of principal executive of ice) (Zip code) (858) 964-3720 (Registrant's ...